证券代码：603259 证券简称：药明康德 公告编号：临 2025-028 无锡药明康德新药开发股份有限公司 关于回购 A 股股份事项前十大股东和前十大无限售条件股东 持股情况的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日召开第三届董事会第二十次会议，审议通过《关于 2025 年第二次以集中竞 价交易方式回购公司 A 股股份的议案》。具体内容详见 2025 年 4 月 9 日公司于 上海证券交易所网站及指定媒体披露的《关于 2025 年第二次以集中竞价交易方 式回购 A 股股份的预案》（公告编号：临 2025-025）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司董事会披露回购股份决议前一个交易 日（即 2025 年 4 月 8 日）登记在册的前十大股东和前十大无限售条件股东的名 称、持股数量及持股比例公告如下： 无锡药明康德新药开发股份有限公司董事会 2025 年 4 ...

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年4月28日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年3月31日止三個月之第一季業績及其發佈。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年4月14日 於本公告日期，董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、 俞衛博士、張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 ...

药明康德(02359.HK)：公司宣布将于2025年4月28日（星期一）召开董事会会议，以考虑及批准（其中 包括）本集团截至2025年3月31日止三个月之第一季业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年4月28日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年3月31日止三個月之第一季業績及其發佈。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 於本公告日期，董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、 俞衛博士、張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 香港，2025年4月14日 ...

港股生物医药板块盘初走强，再鼎医药(09688.HK)涨超12%，君实生物(01877.HK)涨超5%，百济神州 (06160.HK)、药明康德(02359.HK)等跟涨。 ...

Core Viewpoint - The pharmaceutical industry, particularly innovative drugs, is positioned as a key strategic investment direction for China's rise in the context of global supply chain restructuring and geopolitical tensions [1][2]. Group 1: Policy and Market Dynamics - The "Healthy China 2030" initiative aims for the health service industry to reach a total scale of 16 trillion yuan by 2030, with R&D investment intensity surpassing that of developed countries [1]. - The 2024 government work report emphasizes accelerating the development of new productive forces, with biomedicine identified as a key area for increased fiscal support [1]. - The "14th Five-Year" plan for biomedicine aims for the biomedicine sector to account for over 40% of a projected 22 trillion yuan bioeconomy by 2025 [1][2]. Group 2: Innovation and Approval Processes - The average approval cycle for domestic innovative drugs has been reduced to 6.2 years in 2023, a decrease of 3 years since 2018 [2]. - The dynamic adjustment mechanism for medical insurance negotiations will include 7 new anti-cancer drugs in 2024, with price reductions limited to 40%, thereby protecting innovation returns [2]. Group 3: Market Growth and Demographics - The proportion of the population aged 60 and above in China is expected to exceed 21% in 2024 and reach 30% by 2035, driving demand for chronic disease medications, cancer drugs, and rehabilitation equipment [2]. - Per capita medical expenditure in 2023 is 6,200 yuan, only one-sixth of that in the United States, with expectations to exceed 8,000 yuan by 2025 [2]. Group 4: Internationalization and R&D Efficiency - In 2023, the overseas licensing transaction volume for Chinese innovative drugs exceeded 40 billion USD, up from 15 billion USD in 2021, with projections to surpass 50 billion USD in 2024 [3]. - The cost of clinical trials in China is only 30%-50% of that in the United States, significantly shortening the R&D cycle for local pharmaceutical companies [3][4]. - The proportion of innovative drugs in China's pharmaceutical market is projected to increase from 25% in 2023 to 40% by 2025 [2][4]. Group 5: Industry Trends and Future Outlook - The revenue share from innovative drugs going abroad is expected to rise from 8% in 2023 to 20% by 2025, indicating a growing international presence [4]. - The number of global biotech companies with a market value exceeding 100 billion yuan is anticipated to increase, with 3-5 such companies expected to emerge in the coming years [4].

Summary of WuXi AppTec's Conference Call Company Overview - **Company**: WuXi AppTec - **Industry**: Biotechnology and Pharmaceutical Services Key Financial Metrics - **2024 IFRS Net Profit**: 3.24 billion RMB, up 20.4% year-on-year [2] - **Total Revenue**: 39.24 billion RMB, with a 5.2% increase excluding COVID-19 commercialization projects [2] - **Adjusted Non-IFRS Net Profit**: 10.58 billion RMB, down 2.5% year-on-year, with a net profit margin of 27% [2][3] - **Active Clients**: Approximately 6,000, with 5,500 in ongoing operations, adding 1,000 new clients in 2024 [2][4] - **Backlog Orders**: 49.31 billion RMB, a 17% increase year-on-year [5] Revenue Performance by Region - **U.S. Revenue Growth**: 7.7% year-on-year, excluding COVID-19 projects [6] - **European Revenue Growth**: 14.4% year-on-year [6] - **Decline in China and Other Regions**: Revenue decreased in China, Japan, and South Korea, indicating a need for diversification [6] Business Segment Performance - **Wuxi R&D Center Revenue**: 29.05 billion RMB, up 11.2% year-on-year excluding COVID-19 projects [2][8] - **Small Molecule DCM Pipeline**: Expanded to 3,377 molecules, with over 460,000 new compounds delivered, a 10% increase [2][8] - **Testing Revenue**: 5.67 billion RMB, down 8%, with drug evaluation services declining by 13% [9] - **Clinical CRO and SMO Revenue**: 1.81 billion RMB, up 15.5% [9] - **Biology Revenue**: 2.55 billion RMB, flat year-on-year [9] Sustainability Achievements - **Sustainability Ratings**: Achieved 3A rating for four consecutive years and inclusion in the Dow Jones Sustainability Index [7] - **Certifications**: Received gold certification and CDP safety A and B ratings in 2024 [7] Capital Management and Shareholder Returns - **Share Buybacks**: Completed four buyback programs totaling over 4 billion RMB [4][13] - **Dividends**: Maintained a 30% dividend payout ratio, distributing approximately 2.84 billion RMB in cash dividends, plus an additional 1 billion RMB special cash dividend [4][13] Future Outlook - **Revenue Growth Projection for 2025**: Expected to grow by 10% to 15%, targeting total revenue of 41.5 to 43 billion RMB [14] - **Capital Expenditure**: Anticipated to reach 7 to 8 billion RMB, with free cash flow projected at 4 to 5 billion RMB [14] - **H-Shares Incentive Plan**: Plans to implement an H-share reward trust plan to retain talent and promote long-term growth [14] Additional Insights - **Operational Efficiency**: Continuous improvement in production efficiency and capacity utilization [11][12] - **Market Resilience**: Diversified revenue streams contributing to stable performance despite regional declines [6]

Core Viewpoint - WuXi AppTec is facing potential impacts from the recent U.S. tariffs on pharmaceuticals, but the extent of this impact remains unclear. The company is focused on optimizing its supply chain and improving operational efficiency to mitigate these effects while maintaining its revenue guidance for the year [1][2]. Financial Performance - In 2024, WuXi AppTec reported revenues of RMB 39.241 billion, a year-on-year decrease of 2.73%. Excluding specific commercial production projects, revenue grew by 5.2%. The net profit attributable to shareholders was RMB 9.450 billion, down 1.36% year-on-year [2]. - As of the end of 2024, the company's backlog for ongoing operations was RMB 49.31 billion, reflecting a 47.0% year-on-year increase. Revenue from U.S. clients was RMB 25.02 billion, showing a year-on-year growth of 7.7% (excluding specific projects) [2]. Market and Operational Strategy - WuXi AppTec has a significant portion of its revenue (over 50%) coming from the U.S. market, which raises concerns regarding the impact of tariffs. The company has historically concentrated its production capacity domestically due to cost advantages [2]. - The company is expanding its global production capacity, with plans to double the oral formulation capacity at its Swiss facility in 2024 and to complete the Middleton, U.S. facility by the end of 2026. A new R&D and production base in Singapore is also set to begin construction in May 2024, with phase one expected to be operational by 2027 [4]. Business Focus and Asset Management - WuXi AppTec is focusing on its core CRDMO (Contract Research, Development, and Manufacturing Organization) business model and has recently sold stakes in its WuXi ATU business in the U.S. and U.K. to ensure uninterrupted service for clients [4][5]. - The company is continuously evaluating its business development and strategic direction to enhance collaboration across its business segments and better meet the evolving needs of global clients [5]. Regulatory and Competitive Landscape - The U.S. National Security Council recently reported concerns about China's rising dominance in the biotechnology sector, urging the U.S. to take swift action to maintain competitiveness. WuXi AppTec has responded to these claims, asserting that it has never transferred U.S. client data or intellectual property without authorization [5]. Stock Performance - As of April 10, 2024, WuXi AppTec's stock closed at RMB 52.30 per share, up 2.05%, but has declined approximately 25% from its mid-March peak, with a current market capitalization of RMB 151 billion [6].

Core Viewpoint - WuXi AppTec has responded to recent allegations made by the U.S. National Emerging Biotechnology Security Council, asserting that the company has never unauthorizedly transferred U.S. clients' data or intellectual property to third parties [1] Group 1: Company Response - The company’s Vice Chairman and Global Chief Investment Officer, Hu Zhengguo, emphasized the baseless nature of the claims made in the 215-page report by the U.S. council [1] - WuXi AppTec has communicated with relevant U.S. government agencies to clarify the facts surrounding these allegations [1] Group 2: Industry Context - The U.S. National Emerging Biotechnology Security Council's report claims that WuXi AppTec is "deeply embedded in the U.S. biopharmaceutical supply chain" [1]

Market Overview - A-shares and Hong Kong stocks experienced a significant rebound, with A-shares seeing over 5,200 stocks rise and the ChiNext Index increasing by over 4% [1] - The Hang Seng Technology Index rose over 6%, while the Hang Seng Index increased by over 4% [5] Economic Indicators - The postponement of tariffs by Trump is viewed as a clear positive for the market, contributing to the overall rise in the Asia-Pacific markets [1] - A survey by Harvard Business School professor Meg Rithmire indicated that 70% of the 40 members surveyed plan to maintain or increase their business with China, alleviating concerns about the impact of tariffs on corporate operations [7] Sector Performance - The cross-border payment sector saw active trading, with stocks like Feitian Chengxin and Qingdao Jinwang hitting the daily limit, while others rose over 10% [2] - The domestic consumption sector, particularly dairy and retail, showed strong performance with stocks like Yiyaton and Wangfujing hitting the daily limit [3] - The chemical raw materials sector also performed well, with Zhongyida hitting the daily limit and Hengguang shares rising over 10% [4] Corporate Strategies - Some listed companies are accelerating their overseas production capacity to mitigate cost pressures from tariffs, with plans to establish manufacturing bases in low-tariff countries [6] - Companies are also shifting sales markets towards Europe and India, utilizing Southeast Asian bases to meet regional demand [6] Investment Sentiment - The market's risk appetite has increased, as evidenced by the decline in government bond futures, indicating a more optimistic outlook among investors [5]